The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000180.4(GUCY2D):c.164C>T (p.Thr55Met)

CA232809

143061 (ClinVar)

Gene: GUCY2D
Condition: GUCY2D-related recessive retinopathy
Inheritance Mode: Autosomal recessive inheritance
UUID: 756ab94c-c8ea-44a0-8617-cd769e850c35
Approved on: 2025-01-30
Published on: 2025-01-30

HGVS expressions

NM_000180.4:c.164C>T
NM_000180.4(GUCY2D):c.164C>T (p.Thr55Met)
NC_000017.11:g.8003211C>T
CM000679.2:g.8003211C>T
NC_000017.10:g.7906529C>T
CM000679.1:g.7906529C>T
NC_000017.9:g.7847254C>T
NG_009092.1:g.5542C>T
ENST00000254854.5:c.164C>T
ENST00000254854.4:c.164C>T
NM_000180.3:c.164C>T
More

Likely Benign

Met criteria codes 2
BS1 BS2_Supporting
Not Met criteria codes 2
BP4 PP3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GUCY2D Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
The NM_000180.4(GUCY2D):c.164C>T (p.Thr55Met) variant is predicted to replace the threonine at position p.55 with methionine. This variant is present in gnomAD v4.1.0 at a Grpmax allele frequency of 0.008088, with 341 alleles / 38476 total alleles in the East Asian population, which is higher than the ClinGen LCA/eoRD VCEP BS1 threshold of >0.0016 (BS1). This variant has been found in the homozygous state in 3 adult individuals in gnomAD which meets the LCA/eoRD VCEP threshold of ≥3 (gnomAD version 4.1.0; BS2_supporting). In addition, the reported frequency of this variant in the Vietnamese population is 1.5%. (PMID:31180159). The computational predictor REVEL gives a score of 0.409, which is below the ClinGen LCA / eoRD VCEP threshold of ≥0.644 and does not predict a damaging effect on GUCY2D function. Additionally, the splicing impact predictor SpliceAI gives a score of 0, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing. Several papers describing East Asian IRD cohorts (PMIDs: 21602930, 23847139) report the presence of the variant in patients but since this is the population with the highest reported allele frequency these papers were not counted toward PM3. In summary, this variant meets the criteria to be classified as Likely Benign for GUCY2D-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BS1. (VCEP specifications version 1.0.0; date of approval 01/22/2025).
Met criteria codes
BS1
This variant is present in gnomAD v.4.1.0 at a Grpmax allele frequency of 0.008088, with 341 alleles / 38476 total alleles in the East Asian population (including 3 homozygotes), which is higher than the ClinGen LCA / eoRD VCEP BS1 threshold of >0.0016 (BS1). In addition, the reported frequency of this variant in the Vietnamese population is 1.5%. (PMID:31180159)
BS2_Supporting
This variant has been found in the homozygous state in 3 adult individuals in gnomAD which meets the LCA/eoRD VCEP threshold of ≥3 (gnomAD version 4.1.0; BS2_supporting).
Not Met criteria codes
BP4
The computational predictor REVEL gives a score of 0.409, which is above the ClinGen LCA / eoRD VCEP threshold of <0.290 and does not predict a non-damaging effect on GUCY2D function.
PP3
The computational predictor REVEL gives a score of 0.409, which is below the ClinGen LCA / eoRD VCEP threshold of ≥0.644 and does not predict a damaging effect on GUCY2D function. Additionally, the splicing impact predictor SpliceAI gives a score of 0, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.